Grants for County governments - Federal

The National Aeronautics and Space Administration (NASA) Headquarters has released a solicitation, titled Early Stage Innovations (ESI), as an appendix to the Space Technology Mission Directorate (STMD) umbrella NASA Research Announcement (NRA) titled "Space Technology Research, Development, Demonstration, and Infusion 2024 (SpaceTech REDDI 2024), on April 4, 2024. The ESI solicitation is available by opening the NSPIRES homepage at https://nspires.nasaprs.com/, selecting Open under "Solicitations," and searching "Early Stage Innovations (ESI24)" under Keywords. The Space Technology Research Grants (STRG) Program within STMD seeks proposals from accredited U.S. universities to develop unique, disruptive, or transformational space technologies that have the potential to lead to dramatic improvements at the system level performance, weight, cost, reliability, operational simplicity, or other figures of merit associated with spaceflight hardware or missions. The projected impact at the system level must be substantial and clearly identified. Only accredited U.S. universities are eligible to submit proposals. Teaming is permitted see solicitation for complete eligibility requirements as well as teaming restrictions. A Principal Investigator (see solicitation for restrictions) or Co-Investigator may participate in no more than two proposals in response to this solicitation. NASA encourages submission of ESI proposals on behalf of tenure-track or tenured faculty members at all U.S. universities and especially encourages proposals submitted on behalf of and/or that include as team members women, members of underrepresented minority groups, and persons with disabilities. The solicitation exclusively seeks proposals that are responsive to one of the following two topics: Topic 1 Computational Materials Engineering for Lunar Metals Welding Topic 2 Passive Lunar Dust Control through Advanced Materials and Surface Engineering NASA anticipates addressing other topics in future ESI Appendix releases. The financial and programmatic support for ESI comes from the Space Technology Research Grants Program within the Space Technology Mission Directorate. Awards are planned to start in January 2025. NASA plans to make approximately 6 awards as a result of this ESI solicitation, subject to the receipt of meritorious proposals. The actual number of awards will depend on the quality of the proposals received; NASA reserves the right to make no awards under this solicitation. STMD is strongly committed to ensuring that proposal review is performed in an equitable and fair manner that reduces the impacts of any unconscious biases. To this end, this Appendix will employ a Dual-Anonymous Peer Review (DAPR) process to evaluate proposals. Using DAPR, not only are proposers not told the identities of the reviewers, but the identities of the proposers (personnel and organization names) will not be shared with the reviewers until after the technical review of all anonymized proposals has been completed. All proposals must be submitted electronically through NSPIRES by an authorized organizational representative. Notices of Intent (strongly encouraged) are due by May 9, 2024, with proposals due on or before June 6, 2024, 5 pm Eastern. Detailed submission instructions and due dates are provided in the solicitation. Potential proposers and their proposing organizations are urged to familiarize themselves with the submission system, ensure they are registered in NSPIRES, and submit the required proposal materials well in advance of the deadline. All technical and programmatic comments and questions may be addressed by email to the Space Technology Research Grants Program Executive, at [email protected]. Responses to inquiries will be answered by email and may also be included in the Frequently Asked Questions (FAQ) documents located on the NSPIRES page associated with the solicitation; anonymity of persons/institutions who submit questions will be preserved.

Questions regarding this Funding Opportunity Announcement (FOA) Forecast may be emailed to [email protected]; however, please note there is limited information that may be shared with the public, as this FOA is currently under development. We encourage prospective applicants and interested parties to use the Grants.gov subscription option to register for future updates provided for this particular FOA.

This funding opportunity supports innovative clinical research to explore the brain mechanisms behind substance use disorders, targeting a wide range of researchers and institutions dedicated to addressing addiction challenges.

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

This funding opportunity provides financial support for researchers to analyze and integrate existing data to better understand cancer risk, prevention, and treatment outcomes, particularly focusing on innovative methodologies and addressing health disparities.

The FY24 PCRP Early Investigator Research Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. All application components for the FY24 PCRP Early Investigator Research Award are to be written by the Principal Investigator (PI), with appropriate direction from the mentor(s).Key elements of this award mechanism are as follows: Principal Investigator: The postdoctoral investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI is not required to have previous prostate cancer research experience. The PI must have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) as of March 31, 2025. The PCRP strongly encourages applications from PIs who demonstrate a commitment to pursuing a career focused on prostate cancer health disparity research. Mentor(s): Applications must include at least one mentor appropriate to the proposed research project who has experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. The primary mentor can be a junior faculty member, in which case the PI is encouraged to include a secondary mentor with a more robust track record in prostate cancer research and mentorship. Applications that focus on prostate cancer health disparity should include at least one mentor with experience in prostate cancer health disparity research. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a prostate cancer researcher. Research Approach: Proposed research ideas are required to address one or more of the FY24 PCRP Overarching Challenges. Projects that specifically address the FY24 PCRP Overarching Challenge to advance health equity and reduce disparities in prostate cancer are strongly encouraged. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The feasibility of the research design and methods should be well defined, and a clear plan should be articulated as to how the proposed goals of the project can be achieved. Inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required. Any preliminary data provided should be from the PI, mentor(s), or member(s) of the collaborating team. Additionally, required resources should be identified and supported through documentation. Research involving human subjects and human anatomical substances is permitted; however, clinical trials are not allowed under this funding opportunity. Researcher Development Plan: The PI must outline an individualized, prostate cancer-focused researcher development plan, which should include a clearly articulated strategy for acquiring the necessary skills, competence, and expertise that will enable the PI to successfully complete the proposed research project and foster the PIs development as an independent prostate cancer researcher. An environment appropriate to the proposed mentoring and research project must be clearly described, although any deficiencies of resources and/or mentorship at the PIs institution can be mitigated through collaboration(s) with other institutions. If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution.Investigators are strongly encouraged to incorporate the following components into their study design, where appropriate, in order to maximize the potential impact of the proposed research project: authentication of proposed cell lines; statistical rigor of preclinical animal experiments; and incorporation of experiments to assess clinical relevance and translatability of findings. Studies utilizing data derived from large patient studies that include long-term health records, biospecimen repositories, and pre-existing research and apply state-of-the-art genomic and/or proteomic analysis, bioinformatics, and/or mathematical models to such data are also encouraged. Investigators are highly encouraged to provide a letter of support indicating access to and the availability of any resources required to support the study.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more-effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Early Investigator Research Award should not exceed $300,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.24M to fund approximately 13 Early Investigator Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

With this solicitation, BJA seeks to support new and innovative strategies for preventing and reducing crime, improving community safety, and strengthening criminal justice system outcomes. BJA seeks to accomplish this by promoting collaborations with the field to identify, define, and respond to emerging or chronic crime problems or justice system challenges. BJA is looking for strategies that address these issues, including trying new approaches, addressing gaps in responses, building or translating research knowledge, or building capacity.

This funding opportunity supports multidisciplinary research aimed at improving the understanding and treatment of asthma and allergic diseases, inviting applications from various institutions and organizations involved in clinical and translational research.

This grant provides funding to specialized clinics for collecting and analyzing long-term health data on individuals with spina bifida, aiming to improve care and health outcomes for patients of all ages.

This grant provides funding to support research and initiatives that promote diversity, equity, inclusion, and accessibility for individuals with disabilities in STEM fields and education.

This funding opportunity supports innovative research projects that explore how T-cells contribute to HIV infection and related brain complications, targeting researchers from various institutions and organizations.

This funding opportunity supports innovative educational projects that engage K-12 students and teachers in the biomedical and behavioral sciences, particularly targeting individuals from diverse and underrepresented backgrounds.

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists trained in clinical and translational cancer research, and to promote their career development as cancer researchers. This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.

This grant provides funding to improve collaboration among early childhood education providers and stakeholders to support the development and learning of low-income migrant and seasonal worker children and families.

This cooperative agreement would establish a Center for Home-based Child Care Research to support research about home-based child care (HBCC) in states, territories, This cooperative agreement would establish a Center for Home-based Child Care Research to support research about home-based child care (HBCC) in states, territories, tribes, and/or local community contexts. The purpose of the Center is to provide leadership, build research capacity in the field, and offer support in the development and facilitation of local research to improve understanding of HBCC settings and providers as well as access by the families who seek and utilize HBCC. This research center would promote sound research examining HBCC supply and the factors that support or suppress the availability of HBCC in communities. In addition, this Center would advance the fields understanding of HBCC engagement in public programs and quality improvement efforts. The Centers activities would build research and evaluation capacity in the field and support research in states, territories, and/or tribes that could inform local initiatives designed to sustain and strengthen HBCC.HBCC providers, or individuals and small business owners paid to provide child care in private residences or homes, are an essential segment of the child care landscape. They constitute the largest portion of the child care and early education (CCEE) workforce and serve the vast majority of children birth through school-age who are in regular nonparental care. It is critical for the Administration for Children and Families and for local communities to learn more about HBCC providers, both the individuals providing the care and the characteristics of the programs where they provide child care, in order to inform federal efforts and state, territory, tribal and/or local initiatives to increase access to safe and high-quality child care particularly for families with lower-incomes and working families. The Center would promote sound research examining HBCC and the factors that support or suppress the availability of HBCC in states, territories, and/or tribes. In addition, this Center would advance the fields understanding of HBCC providers engagement in publicly funded programs (e.g., child care subsidies, Head Start) and quality improvement efforts (e.g., Quality Rating and Improvement Systems (QRIS), quality initiatives (QI), and continuous quality improvement (CQI) initiatives). The Centers activities would build research and evaluation capacity in the field and support research in state, territories and/or tribes that could inform local initiatives designed to sustain and strengthen the supply of HBCC. This Center would ideally bring together a team that has experience investigating HBCC, evaluating Child Care and Development Fund (CCDF) program and policies, and assessing the needs and experiences of families with lower-incomes, in tribal communities, and of historically marginalized populations. This Center would be equipped to strengthen the ability of local research partnerships to conduct model research projects that effectively address questions concerning HBCC in local contexts, while contributing to broader understanding in the field about HBCC.

This funding opportunity supports small pilot projects that enhance understanding of the human virome, inviting collaborations from various organizations, including educational institutions and nonprofits, to develop innovative tools and methods for studying the interactions between viruses and human health.

The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing innovative transdisciplinary research that integrates approaches across social/cognitive neuroscience and other social sciences and will lead to a testable conceptual or computational model that provides mechanistic insights into social behavior and its relationships with the onset, trajectory and impact of Substance Use Disorders (SUD) and comorbidities. This NOFO is specifically soliciting applications proposing BESH research, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The "Short Courses on Utilizing the NIH Stage Model to Develop Behavioral Interventions to Promote Healthy Aging" grant aims to fund the creation of short educational programs that teach researchers how to use the NIH Stage Model to develop non-drug interventions that encourage healthy aging and improve care for older adults.

The "NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed)" grant aims to provide financial support and entrepreneurial training to postdoctoral researchers and junior faculty in biomedical, social, or behavioral sciences, to foster their transition to research independence and potentially launch careers in industry, scientific business development, or academia, with a special focus on aging and Alzheimer's disease research.